Overview

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies
Phase:
PHASE1
Details
Lead Sponsor:
Bolt Biotherapeutics, Inc.
Collaborator:
Regeneron Pharmaceuticals
Treatments:
cemiplimab
Immune Checkpoint Inhibitors